EFFECTS OF ETHAMIVAN IN PATIENTS WITH CHRONIC RESPIRATORY DISEASE.

摘要: Abstract Nineteen patients suffering from chronic respiratory disease were evaluated before, during and after ethamivan administration by serial measurement of arterial pH, pCO2, plasma levels alveolar ventilation. Ethamivan was administered intravenously as a single injection 50 mg. in five patients; an 25 mg./kg. intravenous (a) over 15 minutes (b) 150 finally oral dose 300 to 500 patients. Plasma became unmeasurable within receiving the largest dose. Alveolar ventilation increased only highest dose, no significant changes blood gases elicited any patient.